首页> 美国卫生研究院文献>Scientia Pharmaceutica >Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study
【2h】

Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study

机译:同时估算人血浆中氨氯地平和缬沙坦的LC-MS / MS方法的开发和验证:在生物等效性研究中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A reliable, simple, and robust liquid chromatography-tandem mass spectro-metric (LC-MS/MS) method has been developed and validated that employs solid-phase extraction for the simultaneous estimation of amlodipine and valsartan in human K3EDTA plasma using amlodipine-d4 and valsartan-d9 as internal standards. Chromatographic separation of amlodipine and valsartan was achieved on the Luna C18 (2)100A (150 × 4.6 mm, 5 μm) column using acetonitrile: 5 mM ammonium formate solution (80:20, v/v) as the mobile phase at a flow rate of 0.8 mL/min in isocratic mode. Quantification was achieved using an electrospray ion interface operating in positive mode, under multiple reaction monitoring (MRM) conditions. The assay was found to be linear over the range of 0.302–20.725 ng/mL for amlodipine and 6.062–18060.792 ng/mL for valsartan. The method has shown good reproducibility, as intra- and interday precisions were within 10% and accuracies were within 8% of nominal values for both analytes. The method was successfully applied for the bioequivalence study of amlodipine and valsartan after oral administration of a fixed dose of the combination. Additionally, as required by the current regulatory bodies, incurred sample reanalysis was performed and found to be acceptable.
机译:已开发并验证了可靠,简单且可靠的液相色谱-串联质谱(LC-MS / MS)方法,该方法采用固相萃取同时使用氨氯地平-d4估算人K3EDTA血浆中的氨氯地平和缬沙坦并以valsartan-d9作为内标。在Luna C18(2)100A(150×4.6 mm,5μm)色谱柱上使用乙腈:5 mM甲酸铵溶液(80:20,v / v)作为流动相在色谱柱上实现氨氯地平和缬沙坦的色谱分离等度模式下流速为0.8 mL / min。在多个反应监测(MRM)条件下,使用电喷雾离子接口以正模式运行可实现定量。氨氯地平在0.302–20.725 ng / mL范围内和缬沙坦在6.062–18060.792 ng / mL范围内呈线性关系。该方法显示出良好的重现性,因为两种分析物的日内和日间精度均在标称值的10%以内,准确度在8%以内。口服固定剂量的联合用药后,该方法已成功用于氨氯地平和缬沙坦的生物等效性研究。此外,根据当前监管机构的要求,对样品进行了重新分析,结果是可以接受的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号